News

UPDATED: NewLink, Merck sign Ebola vaccine licensing pact

To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.

Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results

Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.

India's Cipla breaks into vaccines with Serum deal in Europe

Indian generics maker Cipla is taking its low-cost game into the vaccine field, thanks to a new deal with the Serum Institute of India.

PATH chooses Mymetics for work on transmission-blocking malaria vaccine

With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.

U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing

Earlier this month, U.K. politicians asked Prime Minister David Cameron to explain why Novartis' Bexsero, approved as an addition to the country's childhood immunization schedule 8 months back, had yet to be covered by the National Health Service. Now, Cameron has asked Health Secretary Jeremy Hunt to do the same--and Hunt is pointing the finger at the Swiss pharma.

NewLink Ebola vaccine trial to start in Canada

In Canada, which has no reported cases of Ebola, people are lining up to get in on a clinical trial for an Ebola vaccine.

Pfizer's MenB reach--and lead on Novartis--limited without ACIP nod

As Pfizer's Trumenba rolls out in the U.S., it may get a head start on Novartis' Bexsero, which is still awaiting FDA approval. But the drug giant still doesn't yet have what it needs to build a considerable lead: a recommendation from the CDC's Advisory Committee on Immunization Practices.

Celldex glioblastoma vaccine extends survival in Phase II

In a Phase II trial, Celldex Therapeutics' cancer vaccine rindopepimut, or Rintega, helped recurrent glioblastoma patients who took it with Roche's Avastin survive a median of 3.2 months longer than patients who took Avastin alone. 

U.K. pols press PM Cameron on Bexsero coverage delay

Ongoing price negotiations between the U.K. government and Novartis have so far kept the meningitis B vaccine Bexsero out of the public's reach, and now members of Parliament are asking where it is.

Report: Sanofi has billion-dollar dengue opportunity in India

Analysts have said Sanofi's dengue vaccine, once approved, could rake in €1 billion, or $1.31 billion, a year. According to a report from Brandeis University, the number of dengue cases in the India is almost 300 times higher than government figures.

Study: Universal E. coli vaccine appears possible thanks to limited number of strains

Development of a vaccine to protect against the Escherichia coli (E. coli) bacterium has been stymied because the genetic structure of the many strains of E. coli varied hugely. But according to a new study, the diversity of E. coli's numerous strains is not as vast as previously thought, inspiring hopes that a global vaccine can be developed.

Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate

When Merck's Indian JV, Hilleman Laboratories, teamed up in June with Swedish biotech Gotovax AB, the plan was to get an affordable cholera vaccine to the developing world. Just a few months out, it's inked a pact to make that happen faster.

At long last, Sanofi launches low-cost pentavalent in India

It's been a long road for Shan5, the low-cost pentavalent from Sanofi-owned Shantha Biotechnics. Now, after manufacturing tie-ups four years ago cost the company a $340 million contract to supply the vaccine, it's finally rolling out the product in India.

Dendreon bankruptcy weighs on cancer vaccine field

Ever since Dendreon's lackluster Provenge launch, the Washington-based biotech's failures have cast a pall over the troubled cancer vaccine field. And the company's bankruptcy won't help with that.

Inhaled Ebola vaccine may provide higher protection rate

A breathable, respiratory vaccine to guard against Ebola is the latest contender to join the race toward a treatment or vaccine to stop the spread of the deadly virus. Developed by researchers at the University of Texas at Austin, the vaccine has shown that a single dose of the vaccine showed long-term protection in monkeys.

Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout

Expanded results from Sanofi's Latin American Phase III dengue vaccine trial are here, and the pharma giant says they confirm the high efficacy against severe dengue and the reduction in hospitalization the jab posted in its first Phase III study. And with these in tow, the company says it could have the vaccine to market by the second half of next year.

Glaxo hep C vaccine delivers promising early results

Next-generation hepatitis C drugs may be breaking revenue records now, but eventually a vaccine to prevent the disease could cut into the cash cows' market share. That candidate might come from GlaxoSmithKline, whose hepatitis C vaccine just passed an early test, generating strong and broad immune responses not seen before against the transmissible liver disease.

Sanofi, Protein Sciences win flu jab nods in older adults

A couple of flu vaccine makers have new patient populations to target, thanks to a pair of recent FDA approvals in older adults.

PATH Malaria Vaccines Initiative nets $156M from Gates Foundation

Malaria and the mosquitoes that carry it may soon have more to contend with than mosquito nets and insecticides, thanks to the PATH Malaria Vaccine Initiative and a $156 million grant from the Bill & Melinda Gates Foundation. The award was announced Sunday by Bill Gates, co-chair of the Foundation, in a speech at the American Society of Tropical Medicine and Hygiene's annual meeting.

Novavax nabs FDA fast-track tag as search for H7N9 vaccine continues

Right now, the U.S. government is in search of an H7N9 vaccine that can reach the market to help prevent against a potential pandemic. And a new FDA fast-track designation for Novavax's candidate might help it get there a little sooner.